Datopotamab deruxtecan has been granted Breakthrough Therapy Designation, or BTD, in the U.S. for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer with disease progression on or after treatment with an EGFR tyrosine kinase inhibitor and platinum-based chemotherapy. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo (DSNKY) and AstraZeneca (AZN).
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca reports ‘positive’ results from AMPLIFY Phase 3 trial
- AstraZeneca granted priority review for Imfinzi sBLA
- AstraZeneca sBLA for Imfinzi granted Priority Review in MIBC
- AstraZeneca announces FDA approval for Imfinzi
- AstraZeneca’s Imfinzi approved in U.S. as immunotherapy regimen for LS-SCLC